COLEC12 high TAMs Orchestrate Lenvatinib Resistance and Cancer Stemness in HCC via Paracrine NRG1-HER2/HER3 Signaling
Clinical and Molecular Hepatology · 2026
DOI: 10.3350/cmh.2025.1059 ↗Kurz gefasst
Fachartikel in der Zeitschrift Clinical and Molecular Hepatology, 2026. Verfasst von Jianxing Zhang und 15 weiteren Autor:innen. Beteiligte Einrichtung: State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, …. Hauptthemen laut MEDLINE: Liver Neoplasms, Phenylurea Compounds, Quinolines, Carcinoma, Hepatocellular. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: National Natural Science Foundation of China, Sun Yat-sen University.
Abstract (Originalsprache)
BACKGROUND/AIMS: Lenvatinib resistance remains a critical barrier in advanced hepatocellular carcinoma (HCC) therapy. However, the underlying mechanisms and strategies for reversing resistance remain incompletely understood. METHODS: Integrated transcriptomics of lenvatinib-resistant patient tumors and an acquired-resistance murine model identified a novel macrophage subpopulation. Functional validation employed CRISPR-SAM screening, conditioned medium (CM) assays, subcutaneous/orthotopic xenografts, patient-derived organoids (PDOs), and patient-derived xenografts (PDXs). Mechanistic studies included ChIP-qPCR, co-immunoprecipitation, and pharmacologic targeting. Clinical relevance was assessed in a retrospective cohort. RESULTS: Resistant HCC exhibited significant enrichment of a COLEC12high TAM subset , which correlated with poor survival and treatment response. These TAMs secreted neuregulin-1 (NRG1) , activating HER2/HER3-AKT signaling in tumor cells to drive cancer stemness and lenvatinib resistance. Mechanistically, in TAMs COLEC12 sequestered STAT1 in the cytoplasm, preventing its phosphorylation, and thereby derepressing STAT3-mediated NRG1 transcription. Depletion of NRG1 reversed the stemness phenotypes and resensitized tumors to lenvatinib both in vitro and in vivo. Clinically, high NRG1 expression predicted an inferior lenvatinib response and shorter survival. Crucially, the bispecific anti-HER2/HER3 antibody zenocutuzumab restored lenvatinib efficacy in PDOs, PDXs, and murine models. CONCLUSIONS: Our work establishes the COLEC12high TAM/NRG1 axis as a master regulator of therapeutic resistance and identifies NRG1 as a predictive biomarker, providing a clinically actionable strategy to overcome lenvatinib resistance in HCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- State Key Laboratory of Oncology in South China, Guangdong Provincial Clinical Research for Cancer, Sun Yat-sen University Cancer Center, Guangzhou, China.
- Department of Liver Surgery, Sun Yat-sen University Cancer Center, Guangzhou, China.
Förderung
- National Natural Science Foundation of China
- Sun Yat-sen University
Zitieren
APA
Zhang, J., Qiao, L., Wu, Z., Zuo, D., Huang, S., Liu, S., Huang, Z., Zeng, Y., Li, Y., Yuan, Y., Wang, C., He, W., Qiu, J., Yuan, Y., Niu, Y., & Li, B. (2026). COLEC12 high TAMs Orchestrate Lenvatinib Resistance and Cancer Stemness in HCC via Paracrine NRG1-HER2/HER3 Signaling. Clinical and Molecular Hepatology. https://doi.org/10.3350/cmh.2025.1059
Vancouver
Zhang J, Qiao L, Wu Z, Zuo D, Huang S, Liu S, et al. COLEC12 high TAMs Orchestrate Lenvatinib Resistance and Cancer Stemness in HCC via Paracrine NRG1-HER2/HER3 Signaling. Clinical and Molecular Hepatology. 2026. doi:10.3350/cmh.2025.1059
BibTeX
@article{Zhang2026,
author = {Zhang, Jianxing and Qiao, Liang and Wu, Zongfeng and Zuo, Dinglan and Huang, Shanshan and Liu, Shaoru and Huang, Zhenkun and Zeng, Yi and Li, Yu and Yuan, Yichuan and Wang, Chenwei and He, Wei and Qiu, Jiliang and Yuan, Yunfei and Niu, Yi and Li, Binkui},
title = {COLEC12 high TAMs Orchestrate Lenvatinib Resistance and Cancer Stemness in HCC via Paracrine NRG1-HER2/HER3 Signaling},
journal = {Clinical and Molecular Hepatology},
year = {2026},
doi = {10.3350/cmh.2025.1059}
}
EUVIMED